盖尔德玛的研究表明,Nemluvio在两年内可以安全治疗严重的湿疹,和皮疹. Galderma's study shows Nemluvio safely treats severe eczema itch and rash over two years.

Galderma 对 Nemluvio（一种治疗中度至重度特应性皮炎的药物）的新研究表明，它的耐受性良好，并在两年内改善了瘙痒和皮肤病变等症状。 Galderma's new study on Nemluvio, a treatment for moderate-to-severe atopic dermatitis, shows it is well-tolerated and improves symptoms like itch and skin lesions over two years. Nemluvio 于 2024 年底获得 FDA 批准用于治疗特应性皮炎和结节性瘙痒症，以 IL-31 受体为靶点，以减少瘙痒和炎症。 Nemluvio, approved by the FDA in late 2024 for atopic dermatitis and prurigo nodularis, targets the IL-31 receptor to reduce itch and inflammation. 在雷达会议上介绍的研究证实了其长期安全和有效性。 The research, presented at the RAD Conference, confirms its long-term safety and effectiveness.